PreOmics builds automation solutions, consumables and the BeatBox platform for homogenization, enrichment and proteomic sample preparation of biopsy, tissue, cell line and plasma samples for mass spectrometry–based proteomics. Its products aim to enable unbiased, deep and reproducible proteomic workflows for academic, clinical, biomarker discovery, CRO and biopharma researchers. The company was founded in 2016 as a spin‑out from Professor Matthias Mann’s lab at the Max Planck Institute of Biochemistry. PreOmics plans to develop integrated, automated BeatBox‑based workflow solutions for different experience levels and throughput needs and to expand its global commercial presence. Following a Series B led by Bruker, the company intends to increase R&D, marketing and sales investments and pursue closer workflow collaborations with instrument vendors like Bruker. PreOmics develops and produces innovative technologies for the pre-analytics of samples for mass spectrometry, offering standardized protocols that enable reproducible results and reduced workload compared with conventional methods. The company was co-founded by Garwin Pichler and Nils Kulak in August 2016, leveraging intellectual property from Matthias Mann’s laboratory at the Max Planck Institute for Biochemistry. PreOmics manufactures solutions aimed at improving sample preparation consistency for mass‑spec workflows. The business plans to continue international expansion and to develop additional products. Financially, the company completed a new financing round in late 2018 to support those plans. No operating metrics were provided in the article.

Total raised

$19M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2022